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Abstract
Case studies have shown that low resolution electromagnetic tomography (LoRETA)
neurofeedback is effective for many psychological disorders, but it’s effectiveness for
individuals experiencing persistent post-concussive symptoms (PPCS) is uncertain.
Individuals with PPCS (n = 7) received an eight-week LoRETA neurofeedback and heart rate
variability biofeedback intervention. Change in symptoms, driving simulation performance,
electroencephalographic z-score deviations, and heart rate variability were compared to
PPCS (n = 9) and healthy (n = 8) control groups. Statistical analyses revealed that the
intervention significantly reduced electroencephalographic z-score deviations (p < 0.005)
compared to PPCS controls. Additionally, headache, nausea, and dizziness symptoms were
reduced in the intervention group (p = 0.003) and the PPCS controls (p = 0.001) compared to
healthy controls. Participants responded variably to the intervention, therefore case analyses
were considered and revealed that some individuals responded to the intervention while
others did not. Future studies with larger populations and longer follow-up times may help
evaluate whether there are commonalities between positive responders.
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1

Introduction

1.1 Concussion and Persistent Post-Concussion Symptoms
A concussion (often used interchangeably with mild traumatic brain injury) is defined as
a traumatic brain injury that is induced by biomechanical forces, which results in an array
of signs and symptoms that can include somatic, cognitive, behavioral, or emotional
changes, sleep disturbances and or balance problems. Most concussions resolve
spontaneously, but some studies indicate that as many as 43% of individuals continue to
experience persistent and disabling problems months beyond their injury (1). Persistent
post-concussive symptoms (PPCS) refer to the lack of clinical recovery in 10-14 days for
adults, and four weeks for children (2). Persisting symptoms can lead to a condition
known as post-concussion syndrome (PCS; 2).
PPCS are problematic because they decrease quality of life by several means, such as
reduced social interactions, difficulty continuing previously enjoyed past-times or
resuming pre-injury physical capabilities and employment tasks (3). This is likely a factor
that contributes to approximately 42% of individuals not returning to work in six months
following a concussion (4). Further, 28% of those who do return to work following a
concussion do not return to the same level of work as before their injury (4); many
individuals require modified return to work duties. Returning to work while continuing to
suffer PPCS increases the risk of subsequent concussions (Mansfield et al. 2015) and
unintentional injury, such as falls and motor vehicle accidents (5).
Recent literature has identified that PPCS are associated with various physiological
impairments, including reduced cerebral vasoreactivity as the severity of PPCS increases
(6), and reduced functional connectivity compared to healthy individuals (7). Increases in
PPCS also correlate with reductions in white matter integrity, indicating delayed
processing speed (8). These physiological deficiencies can manifest in numerous ways,
such as reduced attention and focus, increased reaction time, and disruptions in vision; all
factors necessary for the safe operation of a motor vehicle (9)
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1.2 Concussion, PPCS and Driving
Driving requires planning, anticipation, foresight, concentration, inhibition of certain
stimuli, problem-solving, the ability to simultaneously process large amounts of stimuli,
and quick reactions, all of which can be impaired by a brain injury (10). It has been
suggested that individuals who experience a concussion should not drive for 24 hours
(11). But, driving restrictions for individuals with PPCS depends on medical
professional’s discretion, which is influenced by type and severity of symptoms (11).
Usually driving capacity is initially evaluated by a medical professional, but only 49% of
physicians ‘almost always’ provide driving guidance following a concussion (12). A lack
of driving guidance is concerning because failing to do so may result in returning to
driving prematurely. This is illustrated through findings such as 66% of collegiate
athletes continue to drive following a concussion (13). Furthermore, I am not aware of
any research-based recommendations regarding driving with PPCS.
In a subjective questionnaire, more than half of the participants continuing to experience
PPCS 15 months (on average) post-injury indicated that they were experiencing
difficulties with fatigue, concentration, memory, anger and anxiety that impacted their
overall daily activities (14). This study identified that these participants developed coping
mechanisms to compensate for their difficulties while driving, including avoiding rush
hour traffic, breaking up drives and minimizing lane changes. Although these adaptations
may allow these participants to drive, not everyone experiencing PPCS is able to make
these adaptations. For that reason, identifying and trying to fix the source of the problem
would be much more beneficial.
Making matters even more complex, resolution of concussive symptoms does not
necessarily indicate a return to pre-concussion functioning. Individuals who suffered a
concussion but are asymptomatic exhibit reduced driving capabilities, as assessed in a
driving simulator (15). Their deficiencies included more frequently crossing over the
road’s edge and weaving within their lane when navigating curves. Recently concussed
individuals (two weeks to three months post-concussion) also exhibit increased reaction
time during simulated driving performance (16), and delayed traffic hazard perception
(17). Additionally, compared to the general population, accident rates are more than
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double for persons six to nine years following traumatic brain injury (18). The
combination of physiological deficits in those experiencing PPCS, as well as reduced
driving performance in people after a concussion or traumatic brain injury, emphasize the
need to evaluate driving performance in individuals with PPCS.

1.2.1 Simulated Driving
Driving simulators are a valuable alternative to on-road driving assessments because they
provide a safe environment and allow scripted events to happen for each participant (19).
They have successfully been used to evaluate the driving habits of various populations,
including older adults (20), individuals with glaucoma (21), and people with multiple
sclerosis (22). Driving simulation has also proven effective for providing driving
education to adolescent drivers (23, 24). Driving simulation can offer a valid and reliable
assessment of driving performance (19), and reflects real-life driving (25). Furthermore,
simulator-based assessments can also be more sensitive than an external rater to longterm driving performance in individuals with a traumatic brain injury (26).
Limited previous literature has evaluated the effects of concussion and PPCS on driving,
therefore it is difficult to know what variables should be evaluated. Some of the observed
variables have included reaction time from the moment a programmed stimulus appeared
to the time of an evasive maneuver (e.g. pressing the brake or evasive steering; 16), as
well as number of traffic law violations, crashes, lane excursions, lane position and speed
(15).

1.3 Concussion, PPCS and Mental Health
Concussions are often associated with anxiety, depression, mood changes, and poor
global health (27). These difficulties can continue for individuals with PPCS, but it is
unclear whether PPCS is the cause or merely an association. Some evidence suggests that
psychological factors such as legal involvement and premorbid psychological illnesses
contribute to the development and continuation of PPCS (28). Additionally, a lower level
of psychological resilience, increased trait anxiety and embitterment can affect the
emergence and continuation of PPCS (29).
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PPCS also impacts aspects of life satisfaction. For example, individuals with PPCS report
a low self-assessed quality of life (30). Reported difficulty initiating and staying asleep
(31), as well as migraine and tension-type headaches (12), also contribute to life
dissatisfaction. Following a concussion, depression is associated with greater
psychosocial dysfunction, more psychological distress, and more neurobehavioral
dysfunction (27). This results in a negative cycle, where difficulty continuing normal
activities results in a reduction of those activities, which increases psychosocial
dysfunction and psychological distress, and the cycle continues.
Mood disruptions resulting from (or in combination with) PPCS can influence
fundamental components of driving. Individuals with major depressive disorders perform
worse on working memory tasks (32), have slowed reaction time, and are susceptible to
fatigue (33). Additionally, increased anxiety can draw focus to threat-related stimuli,
which reduces concentration and information processing (34). Increases in impulsivity,
irritability and aggression (35) can also result in dangerous and at-risk driving
behaviours.

1.4 Generalized Anxiety Disorder Scale
Anxiety is one of the most common PPCS (35). The 7-item Generalized Anxiety Scale
(GAD-7) detects generalized anxiety, and can also detect post-traumatic stress disorder,
panic disorder and social anxiety disorder (36). It is a reliable and valid measure of
anxiety in the general population (37), the elderly (38) and in primary care (39). It is
preferred for individuals with PPCS because they often experience vision difficulties and
headaches with prolonged reading and concentration, and this questionnaire is very short.

1.5 Rivermead Post-Concussion Symptoms Questionnaire
Questionnaires have been created to evaluate some of the most common concussion
symptoms. The Rivermead Post-Concussion Symptoms Questionnaire (RPQ) is a 16-item
questionnaire that evaluates the severity of symptoms such as headache, dizziness,
nausea, poor concentration, forgetfulness, etc. It demonstrates good test-retest and interrater reliability (40). Furthermore, when evaluating headaches, dizziness and nausea
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separately from the remaining 13 items, it has a good test-retest reliability and validity at
three months post injury (41). It is also very short, and therefore is easy for individuals
with PPCS to complete.

1.6 Treatment of Concussion and PPCS
Since the return protocol for acute concussions is well-established (2), it can easily be
adhered to and implemented by medical professionals. When an individual suffers a
concussion, they often are instructed to follow a graded return to work/learn/play
protocol. They begin with a 24-48 hour cognitive and physical rest period. Afterwards,
they continue gradually returning to everyday activities, while reducing this activity if
symptoms increase (2). This protocol facilitates proper immediate treatment, and may
help increase the likelihood of resolution.
PPCS, however, is much more difficult to treat because the best practices for
rehabilitation programs have not yet been universally adopted. Individualized treatment
plans that target medical, physical and psychosocial symptoms are recommended (2).
Accordingly, specialists like physiotherapists, occupational therapists, speech and
language specialists, optometrists, or massage therapists may be consulted. Patients may
also seek psychological treatment to aide common symptoms like depression, anxiety, or
mood changes (42).
Although these specialists may reduce or eliminate symptoms, this is not always the case.
For instance, treating the manifested symptoms does not necessarily address the cause;
the root of the symptom may be due to altered physiology. This is starting to be
researched more. For example, exercise used to be discouraged for individuals
experiencing symptoms following a concussion (43). But, we now know how beneficial
sub-symptom aerobic exercise following a concussion can be (44). Treating the
manifested symptom may be beneficial and allow individuals with PPCS to live with
their injury, but research needs to be done to investigate how to identify the physiological
damage and how to rectify it.
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1.7 Heart Rate Variability
Biomechanical forces that result in concussions affect other organs within the body, not
just the brain (Cernak and Noble-Haeusslein, 2009). Furthermore, if an organ and the
organ’s control center (the brain) are injured, it can result in additional difficulties. For
example, the autonomic nervous assists in controlling the heart, including whether the
heart should increase or decrease its strength and rate of heart beats (45). The specific
regions of the brain that are involved in regulation of the autonomic nervous system are
still debated, but it has been determined that it includes contribution from areas such as
the amygdala and prefrontal cortex (46). This information indicates that there is a brainheart connection, and a disruption to this connection (e.g. following a concussion) can
result in a cascade of symptoms that can include arrhythmias, ischemia, myocardial
infarction, and altered sympathetic or parasympathetic activation (Leddy et al., 2007).
Heart rate variability (HRV) is the natural beat-to-beat variability in heart rate. It is
representative of autonomic function and sympathetic-parasympathetic balance (47). It
can be measured in both time- and frequency-domains, including measures such as the
square root of the mean squared differences of consecutive normal intervals (RMSSD),
and standard deviation of the normal interval (SDNN). SDNN is a good global measure
of variability and it reflects cardiovascular adaptability to individual and environmental
changes (48). Frequency-domain measures include power in various bands (49).
Healthy people normally exhibit a beat-to-beat variation in their heart rate, but HRV is
decreased when the autonomic nervous system is impaired (50). Decreased HRV is
associated with reduced social and emotional functioning, including social cognition,
empathy and alexithymia (48). HRV is altered in those suffering a concussion, including
low amplitude and reduced rhythmicity (Thompson and Hagedorn, 2012). Further, some
individuals suffering PPCS have reduced parasympathetic activity and hyperactive
sympathetic activity and heart rates (51). This is problematic because it results in a
heightened and prolonged state of flight or flight, which may contribute to feelings of
nausea, dizziness, and inability to sleep – all of which are common PPCS (2).
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HRV biofeedback intends to repair sympathetic-parasympathetic balance, as well as
baroreflex activity (Lehrer et al., 2003). Using an electrocardiograph (ECG), it provides
beat-to-beat data to a participant while they maintain a slow, set breathing rate. This set
breathing rate maximizes respiratory sinus arrhythmia, which increases the heart rate
when inhaling, and decreases the heart rate when exhaling (52). Respiratory sinus
arrhythmia works in combination with the information that baroreceptors are detecting
regarding blood pressure to increase the variability of HRV (53). More variability
(increased HRV) reflects increased reflex efficiency, which is a result of more controlled
autonomic activity (54). It also translates to larger oscillations in heart rate, which
promotes increased parasympathetic control and reduced sympathetic control (55).
A recent review on HRV biofeedback research shows that it may positively affect
illnesses such as asthma, COPD, irritable bowel syndrome, cyclic vomiting, recurrent
abdominal pain, fibromyalgia, cardiac rehabilitation, hypertension, chronic muscle pain,
pregnancy induced hypertension, depression, anxiety, post-traumatic stress disorder, and
insomnia (56). HRV biofeedback improves cognitive functioning and emotional
regulation in some individuals experiencing a brain injury (48). It may also contribute to
improved attention (57), enhanced executive functioning (58) and superior problemsolving abilities (59). Research is limited on HRV biofeedback’s effects on PPCS, but it
has been indicated that it may be effective with this patient group in reducing symptoms
(including headache) and increasing mood (60, 61).

1.8 Neurofeedback
Electroencephalograph (EEG) biofeedback (neurofeedback), has been used for decades to
improve rehabilitation and brain function. It has been used to improve attention, impulse
control (62), agreeableness and feelings of confidence and composure (63), and reduce
stress (64). It also helps reduce the symptoms of illnesses such as attention deficit
hyperactive disorder (65), post-traumatic stress disorder (66), depression (67), and
epilepsy (68). Neurofeedback has evolved from measuring brain surface area activity, to
source localization of neural activity. This form of neurofeedback is known as lowresolution electromagnetic tomography (LoRETA) neurofeedback (69). It uses
information from the electrical leads placed on the scalp to derive a 3D representation of
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the activation of various regions of the brain– not just where it has manifested on the
superficial area of the brain/scalp. LoRETA neurofeedback allows the user to see, in real
time, the amplitude of electrical activity at specific brain regions, and they can therefore
self-regulate this electrical activity (69).
Benefits to LoRETA neurofeedback include that it is a non-invasive procedure, and that it
shows functional activity in specific brain regions. LoRETA neurofeedback also enables
individualized rehabilitation, which is one of the biggest limitations of traditional brain
injury interventions (70). Based on operant-conditioning principles, users receive
feedback on their brain activity, which is expressed as z-scores relative to a normative
population (healthy age-matched population). This activation is associated with some
form of audible or visual cue (e.g. music playing or a light turning on), when brain
activity is within the set range compared to the healthy population (i.e. correct). Over
time, users learn to exhibit correct brain activity. With more LoRETA neurofeedback
experience, this trained activity can become more habitual, therefore leading to routine
improvements (71).
LoRETA neurofeedback commonly uses Brodmann areas to classify areas of deviant
brain activity (72-74). Each area is associated with different cognitive functions;
inappropriate brain activity (hyperactive or hypoactive) in different areas can be
associated with specific PPCS (71). Since every PPCS case is unique, it requires an
individualized LoRETA neurofeedback treatment protocol. This makes it difficult to
perform standardized studies, because a blanket treatment will not necessarily work when
each person demonstrates inappropriate brain activity in different areas of the brain.
The majority of research regarding LoRETA neurofeedback treatment for various
ailments is based on case studies. For example, LoRETA neurofeedback improved
memory, attention, and global cognitive scores in eight participants with cognitive
dysfunction and dementia (75). Additionally, LoRETA neurofeedback has provided
cognitive enhancement in individuals with a traumatic brain injury (72). LoRETA
neurofeedback has also proven beneficial for PPCS in small case studies (76).
Accordingly, LoRETA neurofeedback seems to be effective for several clinical
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conditions, but systematic studies with larger sample sizes needs to be completed in order
to evaluate the effectiveness of LoRETA neurofeedback for individuals with PPCS.
LoRETA neurofeedback is often used as a treatment modality in conjunction with HRV.
This is because the neuroanatomical networks and structures that affect and control HRV
can be influenced by neurofeedback; therefore, changes in HRV can cause changes in
these neuroanatomical networks and structures (77). Combining these modalities can be
effective when treating individuals with anxiety and depression (78), as well as
individuals with traumatic brain injury (79).
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2

Purpose and Hypothesis

2.1 Purpose
The purpose of this thesis was to determine whether HRV biofeedback in combination
with LoRETA neurofeedback could reduce symptoms and/or improve simulated driving
performance in individuals suffering from PPCS.

2.2 Hypothesis
1. Individuals with PPCS that receive HRV biofeedback and LoRETA neurofeedback
will have reduced symptoms after an eight-week intervention, compared to a group with
PPCS that does not receive HRV biofeedback and LoRETA neurofeedback.
2. Brain activity in specific areas will be normalized in individuals with PPCS who
receive LoRETA neurofeedback and HRV biofeedback, compared to people with PPCS
who do not receive the intervention, and also to a healthy control group.
3. Individuals undergoing an intervention involving HRV biofeedback and LoRETA
neurofeedback will exhibit greater performance improvements in the driving simulation
task compared to individuals with PPCS who do not receive the intervention, and
compared to a healthy control group.
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3

Methods

3.1 Participants
Thirty-one individuals were recruited to participate in this study; which was approved by
Western University Health Science Research Ethics Board (Appendix A). Participants
with PPCS had to be 18 years of age or older, have previously suffered a clinically
diagnosed concussion, completed the BrainEx 90 concussion rehabilitation program, and
still experiencing ongoing symptoms. They also had to be fluent in English, hold a valid
driver’s license, and be capable of using hand-held devices. Healthy participants also had
to be 18 years of age or older, have not suffered a concussion in the last two years, be
fluent in English, and hold a valid driver’s license.
Participants were withdrawn from the study if they were unable to complete the entire
baseline assessment. This resulted in the loss of seven participants that experienced a
worsening of symptoms and could not complete the driving simulator task. Therefore, 16
participants with PPCS were randomized into the intervention and control groups, and
eight healthy individuals were part of the healthy control group. This resulted in seven
participants in the intervention group (48.6  13 years old, four females), nine
participants in the PPCS control group (54.6  7.6 years old, six females), and eight
healthy control participants (50.1  15.5 years old, four females).
Information about the participants’ PPCS were collected during the baseline assessment.
All PPCS individuals (intervention and control participants) reported that they continued
to experience headaches, along with a variety of other symptoms. Six (of seven)
intervention participants reported experiencing emotional changes (anxiety, anger,
inability to regulate emotions), and four (of seven) reported experiencing balance
problems. Additionally, three (of seven) intervention participants reported experiencing
dizziness, light sensitivity, memory problems, difficulty focusing, and feelings of
overstimulation. Eight (of nine) PPCS controls reported experiencing noise sensitivity,
six reported experiencing light sensitivity, and five reported experiencing emotional
changes (anxiety, anger, inability to regulate emotions) and balance problems.
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3.2 Intervention Protocol
3.2.1 Baseline and Follow-Up Assessment
Participants were initially contacted via email about interest in the study; their response
prompted an informational email. They then met with a study investigator at the iMobile
Research Lab at Western University, where together they reviewed the letter of
information. Once all questions were answered and they signed the consent form, the
baseline assessment began.
The participant was first measured and fitted with a 19-lead EEG cap (Electro Cap
International, Eaton, Ohio). Each electrode placement corresponded to specific locations
on the scalp according to the 10-20 International System for electrode placement (80).
The leads were then filled with a water-soluble conducting gel (Electro-Gel, Electro Cap
International, Eaton, Ohio). An abrasive gel (NuPrep) was used as skin preparation for
the attachment of an electrode to each earlobe. Additionally, one electrode was also taped
to the participants chest, below the left clavicle, for ECG monitoring.
The participant then completed three individual brain function assessments. First, they sat
still and silent for five-minutes for eyes open EEG recordings. As sensitivity to light and
screens can be problematic for individuals suffering PPCS, they were instructed to look at
a spot on the wall. Afterwards, they had a three-minute resting EEG measurement taken
with their eyes-closed. Finally, they performed a 10-minute reaction time test, where they
pressed a button on a handheld toggle when a large blue circle appeared. Before they
completed the actual reaction time test, they had to pass a pre-test that had the same rules,
but provided immediate feedback about whether the responses were correct/incorrect in
pressing/not pressing the button. All of this was completed with the study investigator in
the neighboring room so as to not distract or stress the participant. There was a one-way
window for the study investigator to observe the participant, and the participant was
informed that they could either wave or call on the investigator if they had any questions
or issues.
Brain function assessment was followed by a break. Afterwards, the participant
completed the RPQ and GAD questionnaires (Appendices B and C), and then proceeded
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to the driving simulation task. This was performed on a CDS-200 DriveSafety
simulator, which includes a steering wheel and dash display from a Ford Focus, a gas and
brake pedal, and three computer screens for viewing. The simulator was adjusted for the
participants comfort, ensuring that they were the appropriate distance from the screens,
and they were comfortable with the height and tilt of the steering wheel and distance to
the pedals.
The simulation drive began with three acclimation drives, which are part of an evidencebased simulator sickness mitigation protocol in the iMobile laboratory (24). The
acclimation drives included driving straight down the road at 50 km/hour with no other
vehicles on the road, driving around a city block involving four consecutive left-hand
turns while navigating traffic, and lastly driving around a city block involving four
consecutive right-hand turns while navigating traffic. Between each acclimation drive,
participants were screened for symptoms of simulator sickness using a modified version
of the motion sickness assessment questionnaire (81). Participants rated feelings of
sweatiness, dizziness, and potential to vomit on a scale of 1 (not at all) to 10 (severely).
Participants also had the option to take breaks between drives as needed.
Finally, participants performed one of two simulator drives. Participants were informed
that the drive was supposed to simulate driving in the real world, so they were informed
that other drivers may not obey traffic laws as expected. The two simulator drives
contained identical elements, but in different orders. Both drives ended at a highway onramp, and they were instructed to either go towards London or Toronto, depending on
which simulation drive they were completing. The drive was approximately 10 minutes
in length, and included five scripted events: an unexpected pedestrian crossing the street
in front of the car; a car making a rapid lane change in front of the driver; a sudden
change in traffic lights from green to yellow (go-no-go); a way-finding task
(appropriately picking the ramp to London or Toronto based on earlier instruction); and a
car suddenly pulling out of a driveway in front of the participant. As we are interested in
measures of driving performance that are directly related to safety, we evaluated the
participant’s responses related to two of the scripted events that involve responding to
critical roadway information: the unexpected pedestrian crossing the street in front of the
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car and a car suddenly pulling out of a driveway in front of the car. In specific, we
quantified the participants’ reaction times between the onset of the scripted event (e.g.
first appearance of the pedestrian) until the participant responded by steering or braking.
We also evaluated whether the participants were in a collision during their driving
simulator task. Involvement in a collision ended the driving simulation, which may have
prevented the participant from completing the pedestrian crossing or car pull-out scripted
event. The mean lane deviation for the duration of the driving simulation task was also
evaluated, using the average deviation from the center of the lane.
After eight weeks, all participants returned to complete another brain function
assessment, RPQ and GAD, and driving simulator acclimation and drive. The final
simulator drive was the alternate drive they had not completed in their baseline
assessment. For example, if they completed Drive 1 in their baseline test, then they would
complete Drive 2 in their follow-up assessment.

3.2.2 LoRETA Neurofeedback and HRV Biofeedback
Intervention
Participants in the intervention group received an Android tablet (either a Craig 7" 1GB
6.0 “Marshmallow” Tablet, New York, New York or a Samsung Galaxy Tab A 7’ 8GB
Android 5.1 “Lillipop” Tablet, Seoul, South Korea) and heart rate variability training tool
(Evoke Waveband, Evoke Neurosciences, New York, New York) upon completion of
their initial assessment. They were shown how to use the equipment, and instructed that
they should perform a HRV biofeedback session every morning and night for eight
weeks. Each HRV biofeedback session involved placing the Waveband just below their
elbow, opening the application on their tablet (Mindja, Evoke Neurosciences, New York,
New York), and doing a 5-minute exercise in which they were cued to breathe at their
resonant frequency (approximately six breaths per minute; 82). Points were awarded as
their HRV improved. Participants were also provided with a log book to record the dates
and times of their completed sessions.
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LoRETA neurofeedback is based on measuring EEG signals, comparing them to agematched population norms, and providing feedback to normalize deviant signals. We
performed these measurements using a 19-lead EEG cap (Evoke Neurosciences, New
York, New York). Assessments were completed at the iMobile research laboratory at
Western University, London, Ontario, and interventions were completed in a private
room at Parkwood Institute, London, Ontario. Each participant in the intervention group
was scheduled to participate in three sessions per week (usually Mondays, Wednesdays,
and Fridays), for 8 consecutive weeks. This totaled an expected 24 LoRETA
neurofeedback sessions and 112 HRV biofeedback sessions (24 of which to be completed
with the study investigator during the regularly scheduled neurofeedback training
sessions). Typically, their sessions were at the same time of day.
Based on their initial assessment, an individualized LoRETA protocol was developed for
each participant. This involved identifying the Brodmann areas of the brain and the EEG
frequencies that were most deviant from age-based normal values, and targeting them for
biofeedback. The set of Brodmann areas and frequencies were constant for each of the
participants throughout the study. Each LoRETA neurofeedback session was broken up
into 10 exposures of two-minute duration, for a total of 20 minutes of training.
Participants were instructed to “relax, focus, and turn on the green light”, which would
appear on a computer screen in front of them. The light turned green when the
participants were appropriately activating the target cerebral areas at the appropriate
amplitude. Throughout the duration of the study, as participants achieved more success
(having the green light on >80% of the time), the stringency of their target (the magnitude
of the deviation) was reduced, making it more difficult. The goal was to have the green
light on for 70-80% of the time, creating a balance of reward and challenge.
Following the 20-minute LoRETA neurofeedback training, participants completed a fiveminute HRV biofeedback session. The same HRV biofeedback exercise was completed
as described above (which included a five-minute guided breathing exercise at a rate of
approximately six breaths per minute). This HRV biofeedback session counted as one of
their two daily HRV biofeedback sessions, and was recorded in their log books.
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3.2.3 EEG Collection and LoRETA Neurofeedback
EEG was collected using the eVox System (Evoke Neuroscience, New York, New York),
which is a portable hardware and software system for measuring electrophysiological
data and performing various biofeedback sessions (surface neurofeedback, LoRETA
neurofeedback, and HRV biofeedback). The eVox system consisted of a laptop, an
amplifier, a response button, and a 19-lead EEG cap. When using the system, the cap was
placed on the participant so that the 19 electrodes were situated on the head according to
the 10-20 International System for electrode placement (80). The cap was then connected
to the amplifier, which measured the EEG and ECG data and wirelessly transmitted them
to the laptop. This setup was utilized for the LoRETA neurofeedback and also the EEG
data collection.

3.2.4 Driving Simulator Collection
Performance on the CDS-200 DriveSafety simulator was collected and stored from the
entire drive, with metrics collected at 50 Hz. This included vehicle speed, heading, and
position within the lane. In addition, information was collected during each scripted event
(e.g. the unexpected pedestrian crossing onto the roadway). Data collected also included
metrics such as the distance to objects in the scripted events, and activation of the
steering wheel, brake and gas pedal.

3.3 Data Analysis
3.3.1 RPQ and GAD
Total scores on the GAD for each participant were summed and change from baseline to
follow-up was calculated. Comparisons of this change were analyzed between the
intervention, PPCS control, and healthy control groups using a one-way analysis of
variance (ANOVA). RPQ outcomes were tallied as two scores, similarly to previous
research (41). The headache, nausea and dizziness scores were tallied, and the remaining
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questions were tallied separately. The statistical significance of differences from baseline
to follow-up between the three participant groups in both RPQ sub scores were assessed
using one-way ANOVAs.

3.3.2 Driving Simulation Task
Three parameters were assessed during the driving simulation, including the reaction time
for two of the specific scripted events (the unexpected pedestrian crossing and the car
pulling out in front of the driver’s simulated vehicle). Reaction times were assessed by
evaluating the time difference between the start of the hazardous event and when the
participant applied pressure to the brake or suddenly changed their lane deviation (i.e.
swerving). Additionally, average lane deviation was calculated using the magnitude of
deviation from the center of the lane at 50 Hz throughout the drive. This was measured in
meters, and averaged over the span of the participant’s drive. The statistical significance
of differences from baseline to follow-up between the three participant groups were
analyzed using a one-way ANOVA.

3.3.3 HRV and EEG
HRV was represented by the SDNN parameter (48). SDNN was expressed as a change
from baseline to follow-up, and analyzed using a one-way ANOVA.
Participants’ EEG results included the z-scores of the EEG amplitude for frequencies
between 2 and 30 Hz at all 47 Brodmann areas (83). This yielded a rich data set with a
total of 1288 EEG parameters per participant. Brodmann areas with the most deviation
(12 areas maximum) were identified for all participants in the initial assessment, and
were the chosen intervention target areas. Mean changes from baseline to follow-up
within the designated target Brodmann areas, at all frequencies (2-30 Hz), were
calculated. The statistical significance of differences from baseline to follow-up between
the three participant groups were analyzed using a one-way ANOVA.

18

3.3.4 Statistical Analysis
All statistical analyses were performing using commercial software (SPSS 25, IBM
Corp., Armonk, NY). All one-way ANOVA analyses followed the same protocol.
Outliers were assessed using boxplots, and identified outliers were considered on a caseby-case basis. Normality of the distribution was assessed using a Shapiro-Wilks test.
Levene’s statistic was used to evaluate homogeneity of variances, and if the threshold for
homogeneity of variances was not met, a Welch ANOVA and Games-Howell post hoc
was used. If the homogeneity of variances assumption was met, a Tukey post hoc was
used. The threshold for significance was set at p = 0.05 for all tests. Normality of
distribution and homogeneity of variances are assumed unless otherwise stated.
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4

Results

4.1 Compliance
Participants in the intervention group attended 88% of their LoRETA neurofeedback
sessions (21  2.56; the 25th, 50th, and 75th percentiles were 18.5, 22 and 23,
respectively). The range extended from a low of 17 (one participant) to a maximum of 24
(two participants). Additionally, participants on average completed 86% of their HRV
sessions (96.71  10.14; the 25th, 50th, and 75th percentiles were 86, 99, and 106,
respectively). The range extended from a low of 83 (two participants) to a maximum of
111 (one participant).

4.2 GAD and RPQ
Each group’s average change in GAD scores decreased from baseline to follow-up
(Figure 1). There were no differences (F = 0.528, p = 0.597) between groups, but there
was a large amount of variability in the change data. This variability reflects that some of
the participants in each of the groups showed no change or improvements while others
showed decrements (Figure 2). Additionally, the remaining RPQ measures parameter
identified no significant differences between groups (F = 0.090, p = 0.914; Figure 3).
The one-way ANOVA revealed that there were statistically significant differences in
headache, nausea, and dizziness between the three groups (F = 10.088, p = 0.001). Posthoc testing showed that the healthy control group had significantly greater decreases than
the intervention group (p = 0.003) and the PPCS control group (p = 0.001). The
difference between the intervention group and the PPCS control group was not significant
(p = 0.935; Figure 5). There was also a large amount of variability in both RPQ parameter
measures, therefore individual measures for remaining RPQ measures, along with
headache, nausea, and dizziness, are provided (Figure 4 and Figure 6, respectively).
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Figure 1. Average change in GAD scores between groups. Boxes reflect the
interquartile range, whiskers reflect the minimum and maximum values, and dots
represent outliers.
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Figure 2. GAD Scores for the individual participants. Green indicates participants in
the intervention group, grey indicates PPCS controls, and black indicates healthy
controls.
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Figure 3. Average change in remaining RPQ scores between groups. Boxes reflect
the interquartile range, whiskers reflect the minimum and maximum values, and dots
represent outliers.
50

RPQ Scores for Remaining Measures (Out of 52)

45
40
35
30
25
20
15
10
5
0
Baseline

Follow-Up

Figure 4. RPQ Scores for the individual participants on the remaining items. Green
indicates participants in the intervention group, grey indicates PPCS controls, and black
indicates healthy controls.
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Figure 5. Average change in headache, nausea, and dizziness RPQ scores between
groups. Boxes reflect the interquartile range, whiskers reflect the minimum and
maximum values, and dots represent outliers.
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Figure 6. RPQ Scores for the individual participants on headache, nausea, and
dizziness. Green indicates participants in the intervention group, grey indicates PPCS
controls, and black indicates healthy controls.
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4.3 Driving Simulation
Ten participants were involved in a collision during their driving simulator task. Eight
collisions occurred in the initial assessment (two from the intervention group, four from
the PPCS control group, and two from the healthy control group) and two occurred in
their follow-up assessment (both from the PPCS control group). Accordingly, full drive
metrics were not available for some participants. This resulted in the analysis of changes
in reaction time to a vehicle pulling out in front of the participant in five intervention
participants, five PPCS participants, and four healthy controls. Analysis revealed a lack
of homogeneity of variances (p = 0.024), so a Welch ANOVA was performed. This
analysis identified that there were no significant group differences (F = 2.223, p = 0.167)
between the intervention group (-0.93 s  1.03, 95% CI = -1.89, 0.03), the PPCS control
group (-0.01 s  0.43, 95% CI = -0.40, 0.39) and the healthy control group (-0.37 s 
0.59, 95% CI = -0.87, 0.48).
The participants that were involved in collisions also effectively reduced the number of
participants that were exposed to the pedestrian walking out scripted event. The reaction
time in response to the pedestrian walking out in front of the vehicle was analyzed in six
intervention participants, eight PPCS control participants, and seven healthy controls.
The intervention group had an average reduced reaction time of -0.51 s  0.74 (95% CI =
-1.29, 0.27), the PPCS control group had an average reduced reaction time of -0.31 s 
0.70 (95% CI = -0.90, 0.27) and the healthy control group had an average reduced
reaction time of -0.20 s  0.42 (95% CI = -0.99, 0.25). There were no statistically
significant differences between groups (F = 0.144, p = 0.867). Lastly, there was a trend
towards significant differences in mean lane deviation change between groups (F =
3.102, p = 0.067). The intervention group increased by -0.03 m  0.08 (95% CI = -0.04,
0.11), the PPCS control group increased by 0.10 m  0.10 (95% CI = 0.03, 0.19) and the
healthy control group decreased by -0.01 m  0.11 (95% CI= -0.11, 0.09).
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4.4 HRV
Initial and follow-up SDNN measures were compared between groups, with no
significant differences between groups identified (F = 0.267, p = 0.768). The intervention
group had an average SDNN decrease of -0.86 ms  16.27 (95% CI = -15.90, 14.18),
while the PPCS control group had an average decrease of -7.79 ms  17.10 (95% CI = 20.92, 5.37) and the healthy control group had an average decrease of -4.71 ms  22.83
(95% CI = -25.83, 16.40).

4.5 EEG
One extreme outlier was identified in the healthy control group, therefore their EEG
assessments were excluded from analysis. This approach was similar to other researchers
(84). Differences in EEG did not have homogeneity of variances (p = 0.04). The Welch
ANOVA identified a significant difference between groups (F = 23.262, p < 0.005). The
intervention group had significantly greater normalization of their EEG in the target areas
(smaller z-score deviations) than the PPCS control group (p < 0.0005). There were no
significant differences between the PPCS control group or the intervention group and the
healthy control group (p = 0.448 and 0.113, respectively; Figure 7).
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Figure 7. Average change in the normalized EEG z-score deviations between
groups. Boxes reflect the interquartile range, whiskers reflect the minimum and
maximum values, and dots represent outliers.
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5

Discussion

Our intervention implemented a combination of LoRETA neurofeedback and HRV
biofeedback in individuals with PPCS, and compared a multitude of outcome measures to
participants with PPCS that did not receive the intervention, and a healthy control group.
Individuals that received the intervention exhibited reduced EEG z-score deviations
compared to the PPCS control group. Individuals in the intervention group also reported
frequency and/or severity reductions in headache, nausea, and dizziness compared to the
healthy control group. However, there were also differences between the PPCS control
group and the healthy control group. For example, the PPCS control group’s remainder
RPQ scores showed less of a change in comparison to the healthy control group, likely
reflecting functional impairments in participants with PPCS compared to healthy
controls. There were also no statistically significant differences in GAD scores, driving
simulation performance, or HRV between the three groups. Therefore, our findings
support our hypothesis that LoRETA neurofeedback and HRV biofeedback contribute to
reducing EEG z-score deviations.
Some research has identified that EEG z-scores can represent difficulties balancing
concentration and relaxation (85). This lack of flexibility is problematic because it can
result in wasted energy, or an inability to generate energy for an upcoming task. LoRETA
neurofeedback evaluates the function of specific brain areas, enabling determination of
the link between symptoms and brain function. For example, Brodmann area 10 is
responsible for concentrating on one’s own thoughts or paying attention to the external
environment (86). This was a common neurofeedback target area for the participants with
PPCS in this thesis, which may reflect the concentration difficulties that are typical in
individuals with a concussion (14). Therefore, a reduction in EEG z-score deviations may
have important practical implications. For example, the subset of study participants that
showed reductions in z-score deviations also showed congruous changes in their
concussion symptom scores.
We observed reduced EEG z-score deviations in the intervention group compared to
PPCS controls, but these EEG changes were not associated with reduced PPCS, as
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hypothesized. However, we did observe a large amount of variation in the subjective
assessment outcomes between individuals. When interpreted clinically, this is important
because it represents a disparity in the effectiveness this intervention; some participants
experienced a reduction in symptoms, while others experienced an increase. This was
also noted in the PPCS control group, and further supports the individuality of each
person with PPCS (2). Therefore, similarly to many other PPCS rehabilitation practices,
this intervention does not appear to be effective for everyone with PPCS (87, 88).
Research regarding commonalities between responders would help indicate patients who
would most likely benefit from this treatment.
Similarly to PPCS symptoms, reductions in EEG z-score deviations were not associated
with improvements in driving performance, such as reaction time or lane deviation. But,
the intervention group did exhibit a smaller magnitude increase in the average lane
deviation compared to the PPCS control group. The magnitude of lane deviation in the
intervention group was more similar to the healthy control group than the PPCS control
group; this trend approached statistical significance. The intervention group also
exhibited a trend towards decreased reaction time to respond during both of the scripted
events: when the pedestrian walked in front of the car, and when the car pulled out in
front of the participant, though these changes were not statistically significant. When
applied to actual driving, decreases in reaction time may reduce the risk of a collision
(89). Therefore, larger studies are encouraged in order to definitively evaluate the
effectiveness of this intervention on driving reaction time. It should also be noted that the
confidence intervals were large for each driving simulator parameter, which further
indicates that there was a large amount of inter-individual variation in the effectiveness of
this intervention.
Despite HRV training, there were no significant differences in SDNN between groups,
and the 95% CIs indicated that the changes in SDNN between baseline and follow-up
assessments for all of the groups were also not significant. But this does not necessarily
indicate that the intervention did not have any effect on SDNN. Previous research has
shown increases in SDNN during an intervention, but a return to normal at the end of
treatment and at follow-up (90). Accordingly, the participants in the intervention group
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may have exhibited changes during the intervention that reverted at the end of the study.
Additionally, the intervention group did exhibit a trend toward attenuated SDNN
reduction compared to both groups of controls, with some individuals from the
intervention group showing improvement. Once again, this metric reinforces the
variability of this intervention’s effectiveness.
The large variation in the effectiveness of this intervention between participants indicates
that some individuals responded, and others did not. Accordingly, it is appropriate to
evaluate the features of individual cases to further explore these divergent responses. This
is especially true when each participant in both of the control groups exhibited a range of
changes in the various outcome measures. Two specific cases from the intervention
groups are presented below to illustrate the scope of the responses: one non-responder
and one responder.
Example Non-Responder: Participant 338. This individual attended all of their LoRETA
neurofeedback sessions (24 of 24) and reported that they completed most of their HRV
sessions at home (71%). Following the eight-week intervention, this participant exhibited
a small increase in SDNN (51 ms to 54 ms), which was moving in the direction of the
minimum goal of 65 ms. They also exhibited an increase in deviation in four of the six
identified Brodmann areas following the intervention (Figure 8). However, their
subjective scores on the GAD and RPQ either showed minimal improvement or
worsening following the intervention. Their total for headache, dizziness, and nausea
decreased slightly from seven to six (out of a possible 12), while their remaining RPQ
scores increased substantially from 10 to 20 (out of a possible 52). Finally, their GAD
score increased from two to four (out of a possible 21).
Example Responder: Participant 331: In contrast, participant 331 mainly exhibited
improvements in their outcome measures following the intervention. This participant
attended 83% of their LoRETA neurofeedback sessions, and reported that they completed
95% of their HRV sessions. Following the eight-week intervention, their SDNN reduced
from 28 ms to 24 ms, which is moving away from the minimum goal of 65 ms. They
exhibited significantly reduced deviations in two of the four identified Brodmann areas
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(Figure 9). But, their subjective scores all improved, with headache, nausea and
dizziness decreasing from nine to five. Further, their remaining RPQ scores decreased
from 26 to 8, and their GAD scores decreased from 12 to two. Anecdotally this
participant reported that their symptoms decreased so much that they thought that it may
be appropriate to reduce their anxiety medication.
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Figure 8. Individual Brodmann area (BA) baseline and follow-up deviation in
Participant 338.
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Figure 9. Individual Brodmann area (BA) baseline and follow-up deviation in
Participant 331.
Although there was a large variation in the effectiveness of this intervention between
participants, the concussed participants (intervention and PPCS control groups) also
reported a diverse range of symptoms at baseline. Despite random assignment of
concussed individuals into the intervention and control groups, the participants in the
PPCS control group exhibited a greater range in the RPQ scores for the headache, nausea,
and dizziness parameter, and a smaller range for the RPQ remaining measures parameter.
These apparent differences in baseline subjective symptom scores may have influenced
the effectiveness of the intervention. Furthermore, it is likely that there may be a complex
relationship between the outcome measures in this study. For example, the intervention
may have impacted symptoms, but not driving outcomes. Similarly, the intervention may
have affected driving outcomes, but not SDNN. Other studies have used structural
equation modeling to evaluate similar types of relationships (91), but this was not
possible in the current experiment due to the relatively small number of participants.
This study is not without limitations. One limitation included the fact that we did not
consider the influence of medications that our participants may have been taking. This
study did not consider or evaluate the use of medication, or any changes that may have
occurred while participating. A change in medication could have influenced the
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participants’ outcome scores. An additional potential limitation was that the number of
LoRETA neurofeedback sessions differed between participants, based on compliance.
Although providing neurofeedback three times a week was recommended by a licensed
neurofeedback practitioner (92), some participants communicated that they experienced
extreme fatigue (which contributed to reduced compliance). This may indicate that our
choice of three neurofeedback sessions per week is not optimal. Previous biofeedback
studies have used different number and frequencies of the neurofeedback sessions; one
study used two to three LoRETA neurofeedback sessions per week, for 20 sessions (93)
while another study used daily neurofeedback sessions (94). It is not clear whether the
protocol in this thesis was optimal, and there does not appear to be any consensus on the
best practices for LoRETA neurofeedback. Also, given the individuality of concussions,
it may be that a patient-specific process is required rather than one protocol.
The neurofeedback in this thesis involved simultaneous training of up to 12 Brodmann
areas. Other studies have used a similar criterion for defining which sites should be
targeted for neurofeedback, but have trained a smaller number of concurrent sites (94).
Some of the participants in the intervention group succeeded with the larger number of
concurrent training sites, as illustrated with the responder case report, but some
participants did not appear to successfully normalize their brain activities. It is not clear
whether the relatively large number of sites used for the LoRETA neurofeedback in this
thesis may have contributed to these divergent responses. As well, each participant used
the same training sites throughout the entire intervention while other studies updated the
neurofeedback training sites between sessions (94). While there are merits to maintaining
consistent training sites, it may not be optimal for recovery.
Participants were responsible for reporting their participation in the HRV sessions, which
can result in reporting inaccuracies. However, the investigators had three face-to-face
interactions per week with all of the participants in the intervention group, which
presumably may have increased compliance and reporting of the home HRV sessions.
Our parameterization of the RPQ scores is also a limitation. We divided the RPQ into two
scores by tallying the headaches, dizziness and nausea scores separately from the
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remaining 13 items. This approach is similar to previous research (41), but more recent
research into the structure of the RPQ has identified that it may be better to quantify the
RQP using a four factor model, clustered as vision, vertigo, mood/somatic and cognitive
domains (95). It is unclear how our parameterization of the RQP scores may have
influenced the findings.
This thesis only evaluated a subset of possible variables from the simulated driving
performances. We focused on the reaction time in two of the five scripted events, and on
the average lane deviation parameter. Research supports that reaction time is associated
with individual accident involvement (96), supporting that this parameter has linkages to
safety; however, our parameters may not reflect general aspects of driving skill.
Furthermore, the lane deviation parameter that we analyzed, which evaluated average
deviation over the span of the driving task, may not reflect safety-relevant behavior. For
example, a scenario with one slow lane deviation in each lateral direction may have the
same average lane deviation as a different scenario with more frequent and abrupt lane
deviations, although the implications for safety are different (97). Therefore, abruptness
of lane deviations, as well as number of lane deviations, may be more representative of
at-risk driving behaviours. Furthermore, we did not evaluate driving behaviours such as
visual scanning, that are also related to safety (24).
This study only looked at the immediate effects of the LoRETA neurofeedback and HRV
biofeedback intervention. This approach is consistent with other neurofeedback studies
(62, 63, 98). However, it is not known whether changes will remain in the longer-term.
Alternatively, there may be delays before symptoms change. Some research has
identified that concussion symptoms may have a delayed onset (2), and accordingly a
reduction in symptoms could also be delayed. Therefore, future work is encouraged to
investigate the prolonged effects of LoRETA neurofeedback and HRV biofeedback.
Considering this experiment as a whole, along with two illustrative case reports, it is clear
that our intervention of combined LoRETA neurofeedback and heart rate variability
biofeedback is promising for some individuals. We have not focused on identifying the
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characteristics of individuals that respond, though that is an important avenue for future
research.
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6

Conclusions

In conclusion, interventions that combine LoRETA neurofeedback and HRV biofeedback
are beneficial for some individuals with PPCS. It reduces EEG deviations, reduces
driving simulation reaction time and lane deviation, and reduces symptoms in some
individuals. The effectiveness of this intervention appears to differ between individuals,
and further research is necessary to investigate whether it is possible to identify which
individuals are likely to respond. It is well-understood that certain concussion symptoms
are associated with prolonged duration of symptoms after a concussion (99), and so it
may be that there are commonalities between individuals that respond to this type of
intervention. Furthermore, studies that include longer follow-up times and larger
populations should be performed to clarify and confirm the trends that have been
identified in this study.
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Appendix B: Generalized Anxiety Disorder Scale

The Generalized Anxiety Disorder 7-Item Scale
Over the last 2 weeks, how often have you been bothered by the
following problems?

Not
at all

Several
Days
1

More
than half
the days
2

Nearly
every
day
3

1. Feeling nervous, anxious, or on edge

0

2. Not being able to stop or control worrying

0

1

2

3

3. Worrying too much about different things

0

1

2

3

4. Trouble relaxing

0

1

2

3

5. Being so restless that it is hard to sit still

0

1

2

3

6. Becoming easily annoyed or irritable

0

1

2

3

7. Feeling afraid as if something awful might happen

0

1

2

3

Total Score:

=

Add Columns

_______+ _______+_______

If you checked off any problems, how difficult have these problems made it for you to do your
work, take care of things at home, or get along with other people?
Not at all

Somewhat difficult

______

______

Very difficult

______

Interpreting the Score:
Total Score
≥ 10

Interpretation

5
10

Possible diagnosis of GAD; confirm by
further evaluation
Mild Anxiety
Moderate anxiety

15

Severe anxiety

Extremely Difficult

______
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Appendix C: Rivermead Post-Concussion Symptoms Questionnaire

The Rivermead Post-Concussion Symptoms Questionnaire*
After a head injury or accident some people experience symptoms which can cause worry or
nuisance. We would like to know if you now suffer from any of the symptoms given below.
As many of these symptoms occur normally, we would like you to compare yourself now with
before the accident. For each one, please circle the number closest to your answer.
0
1
2
3
4

=
=
=
=
=

Not experienced at all
No more of a problem
A mild problem
A moderate problem
A severe problem

Compared with before the accident, do you now (i.e., over the last 24 hours) suffer from:
Headaches..................................................
Feelings of Dizziness .................................
Nausea and/or Vomiting ...........................
Noise Sensitivity,
easily upset by loud noise ................
Sleep Disturbance......................................
Fatigue, tiring more easily .........................
Being Irritable, easily angered ..................
Feeling Depressed or Tearful ....................
Feeling Frustrated or Impatient ................
Forgetfulness, poor memory .....................
Poor Concentration ....................................
Taking Longer to Think ..............................
Blurred Vision .............................................
Light Sensitivity,
Easily upset by bright light ................
Double Vision .............................................
Restlessness ..............................................

0
0
0

1
1
1

2
2
2

3
3
3

4
4
4

0
0
0
0
0
0
0
0
0
0

1
1
1
1
1
1
1
1
1
1

2
2
2
2
2
2
2
2
2
2

3
3
3
3
3
3
3
3
3
3

4
4
4
4
4
4
4
4
4
4

0
0
0

1
1
1

2
2
2

3
3
3

4
4
4

Are you experiencing any other difficulties?
1. _______________________________

0

1

2

3

4

2. _______________________________

0

1

2

3

4

*King, N., Crawford, S., Wenden, F., Moss, N., and Wade, D. (1995) J. Neurology 242: 587-592
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